Navigation Links
Cempra, Inc. Reports Fourth Quarter and Full Year 2012 Financial and Operating Results
Date:2/28/2013

CHAPEL HILL, N.C., Feb. 28, 2013 /PRNewswire/ -- Cempra, Inc. (Nasdaq: CEMP), a clinical-stage pharmaceutical company focused on developing differentiated antibiotics to meet critical medical needs in the treatment of bacterial infectious diseases, today reported financial results for the fourth quarter and full year ended Dec. 31, 2012. The company will host a conference call and webcast at 4:30 p.m. EST, today.

"2012 was a transformational year for Cempra," said Prabhavathi Fernandes, Ph.D., chief executive officer of Cempra. "We raised sufficient capital through our IPO and a subsequent private placement to advance our two differentiated antibiotics in clinical development.  Solithromycin is now in the first of two planned Phase 3 clinical trials in community-acquired bacterial pneumonia or CABP and Taksta (CEM-102) is undergoing a Phase 2 trial in patients with prosthetic joint infections or PJIs.  2013 will also be an important year as we expect to hold an end-of-Phase 2 meeting with the FDA during the first half of 2013 for solithromycin in CABP as the key step in preparing for the IV-to-oral second Phase 3 trial, which we expect to start in the second half of 2013 subject to available resources.  We also anticipate presenting some top-line results for the TAKSTA™ Phase 2 trial in PJIs in the fourth quarter of 2013."

Financial ResultsQuarter ended December 31, 2012 compared to quarter ended December 31, 2011

For the quarter ended December 31, 2012, Cempra reported a net loss of $6.6 million, or $0.26 per share, compared to a net loss of $3.8 million, or $7.13 per share, for the same period in 2011. 

Research and development expense in the quarter ended December 31, 2012, was $4.4 million, a 20
'/>"/>

SOURCE Cempra, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. United States Patent and Trademark Office to Require Signed NDA Affects Many Reports Wysebridge
2. China Cord Blood Corporation Reports Financial Results for the Third Quarter and First Nine Months of Fiscal 2013
3. Soligenix Reports Year-End 2012 Financial Results and Highlights Recent Accomplishments
4. InterMune Reports Fourth Quarter And Full Year 2012 Financial Results And Business Highlights
5. Pharmacyclics Reports Results for Six and Three Months Ended December 31, 2012
6. Palatin Technologies, Inc. Reports Second Quarter Fiscal Year 2013 Results; Teleconference and Webcast to be held on February 14, 2013
7. Neuland Labs Reports Third Quarter Fiscal Year 2013 Financial Results
8. Intraocular Lens (IOL) Market Worth $3.8 Billion By 2018 Say New Research Report at ReportsnReports.com
9. Regenerative Medicine and Stem Cells Market Deals Analysis in New Research Report at ReportsnReports.com
10. Cellular Therapy Market and Cord Blood Market 2013 Industry Research Report: MarketResearchReports.Biz
11. Neurocrine Biosciences Reports Fourth Quarter And Year End 2012 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/24/2014)... DUBAI , UAE, November 24, 2014 ... prestigious "Sheikh Hamdan Bin Rashid Al Maktoum Awards for ... in Dubai, United Arab Emirates , ... http://photos.prnewswire.com/prnh/20141124/717861 ) , The Carter Center ... Medical Services is actively involved in numerous programs that ...
(Date:11/24/2014)... Belgium , Nov. 24, 2014 VolitionRx ... developing diagnostic tests for cancer and other conditions, today announced ... presented at the Science for Business BioWin Day 2014, being ... . The data come from VolitionRx,s lung cancer pilot study, ... of the Centre Hospitalier Universitaire (CHU) de Liege in ...
(Date:11/24/2014)... FRANCISCO, Calif. , Nov. 24, 2014   Veracyte, ... Bonnie H. Anderson , president and chief executive officer, ... Jaffray 26 th Annual Healthcare Conference on Tuesday, December ... York . The live audio webcast and ... http://investor.veracyte.com . Please connect to the website at least ...
(Date:11/24/2014)... MD (PRWEB) November 24, 2014 ... underrepresented patient populations into clinical trials at its ... , “Continental was created with the idea ... play a fundamental role in medical advances," said ... Tuskegee syphilis experiment to the immortal cell line ...
Breaking Biology Technology:Five US Winners Among Recipients of Hamdan Medical Awards 2VolitionRx to Present Positive Data from Pilot Lung Cancer Study at BioWin Day 2014 2VolitionRx to Present Positive Data from Pilot Lung Cancer Study at BioWin Day 2014 3VolitionRx to Present Positive Data from Pilot Lung Cancer Study at BioWin Day 2014 4VolitionRx to Present Positive Data from Pilot Lung Cancer Study at BioWin Day 2014 5VolitionRx to Present Positive Data from Pilot Lung Cancer Study at BioWin Day 2014 6Veracyte to Present at the Piper Jaffray 26th Annual Healthcare Conference 2At Continental Clinical Solutions, CEO Saleh Stevens Focuses on Diversity in Clinical Trial Recruitment at Maryland Site 2At Continental Clinical Solutions, CEO Saleh Stevens Focuses on Diversity in Clinical Trial Recruitment at Maryland Site 3
... Universal Detection,Technology (OTC Bulletin Board: UNDT), a ... bioterrorism and other,infectious health threats and provider of ... company,s CEO, Jacques Tizabi,is featured in an exclusive ... interview gives viewers an overview of the company, ...
... Aug. 14 /Xinhua-PRNewswire-FirstCall/ --,China Biologic Products, Inc. (OTC ... the leading plasma-based pharmaceutical companies in,the People,s Republic ... second quarter ended June 30, 2008., ... 35.1% year-over-year to $11.9 million -- Gross ...
... Mass., Aug. 14 Pressure,BioSciences, Inc. (Nasdaq: PBIO ... for the second quarter of 2008 was $120,184 compared ... Revenue from the sale,of PCT products and services was ... compared to $136,355 for the prior year period. During ...
Cached Biology Technology:[video] Jacques Tizabi, CEO of Universal Detection Technology Discusses Latest Purchase Order on WallSt.net's 3-Minute Press Show 2China Biologic Products Reports Second Quarter 2008 Results 2China Biologic Products Reports Second Quarter 2008 Results 3China Biologic Products Reports Second Quarter 2008 Results 4China Biologic Products Reports Second Quarter 2008 Results 5China Biologic Products Reports Second Quarter 2008 Results 6China Biologic Products Reports Second Quarter 2008 Results 7China Biologic Products Reports Second Quarter 2008 Results 8China Biologic Products Reports Second Quarter 2008 Results 9China Biologic Products Reports Second Quarter 2008 Results 10China Biologic Products Reports Second Quarter 2008 Results 11China Biologic Products Reports Second Quarter 2008 Results 12China Biologic Products Reports Second Quarter 2008 Results 13China Biologic Products Reports Second Quarter 2008 Results 14China Biologic Products Reports Second Quarter 2008 Results 15Pressure BioSciences, Inc. Reports Second Quarter 2008 Financial Results and Provides Business Update 2Pressure BioSciences, Inc. Reports Second Quarter 2008 Financial Results and Provides Business Update 3Pressure BioSciences, Inc. Reports Second Quarter 2008 Financial Results and Provides Business Update 4Pressure BioSciences, Inc. Reports Second Quarter 2008 Financial Results and Provides Business Update 5Pressure BioSciences, Inc. Reports Second Quarter 2008 Financial Results and Provides Business Update 6Pressure BioSciences, Inc. Reports Second Quarter 2008 Financial Results and Provides Business Update 7Pressure BioSciences, Inc. Reports Second Quarter 2008 Financial Results and Provides Business Update 8Pressure BioSciences, Inc. Reports Second Quarter 2008 Financial Results and Provides Business Update 9
(Date:11/7/2014)... Auguste, associate professor, biomedical engineering, in the Grove ... New York, have identified a molecule that could ... most aggressive forms of breast cancer. , Triple ... rate owing to aggressive proliferation and metastasis and ... Auguste,s team, discovered the overexpression of intercellular adhesion ...
(Date:11/6/2014)... TALLAHASSEE, Fla. -- A groundbreaking paper from a team ... better understanding of how plants could adapt to and ... The research, published in the latest issue of the ... how chromatin (the complex of DNA and proteins) is ... material, so that some genes are turned on and ...
(Date:11/6/2014)... 2014 - Insilico Medicine, Inc, a Baltimore-based bioinformatics ... related diseases announced a research collaboration with the ... Oncology, Inc (OTC: CSBR). , "There are many ... but Champions Oncology,s TumorGraft technology is unique in ... regimen experimentally generating vast amounts of valuable data. ...
Breaking Biology News(10 mins):Maize analysis yields whole new world of genetic science 2Insilico Medicine, Inc announces research collaboration with Champions Oncology, Inc 2
... a drink problem, there is a greater risk that you ... from the Sahlgrenska Academy, at the University of Gothenburg, Sweden. ... 50% more likely to have a drink problem in the ... new light on this link. Carried out by researcher Anna ...
... LAWRENCE University of Kansas scientists have found new evidence ... (LCPUFA) are good for developing brains and hearts. In ... of four formulas from birth to 12 months; three with ... formula with no LCPUFA, and tested at four, six and ...
... our understanding of genetics and biological processes in all animals, ... of animals, scientists are still finding the fruit fly to ... the University of Rochester. The latest revelation has to ... fruit flies. It was widely accepted that all X chromosomes ...
Cached Biology News:New thinking on regulation of sex chromosomes in fruit flies 2
... number is a new product number, ... number. If showing no availability yet, ... number (E6152) or contact customer service ... diam. 11.25 6.40 in. ...
A convenience pack containing one each of the most popular sizes of Cat. No. 4980 flask. Designed for the low volume user, a case contains one each of five sizes: 50mL, 125mL, 250mL, 500mL, and 1L....
...
...
Biology Products: